-+ 0.00%
-+ 0.00%
-+ 0.00%

The FDA Accepts Its Bioxcel Therapeutics' Supplemental New Drug Application For Igalmi For At-home Use In The Acute Treatment Of Agitation Associated With Bipolar Disorders Or Schizophrenia, PDUFA Date Of November 14

Benzinga·04/01/2026 11:04:13
Listen to the news

Potential first FDA-approved treatment option for the acute treatment of agitation associated with bipolar disorders or schizophrenia in the at-home (outpatient) setting